Johnson & Johnson (JNJ) Cash & Equivalents (2009 - 2026)

Johnson & Johnson has disclosed Cash & Equivalents across 18 years of filings, most recently posting $21.7 billion for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $21.7 billion, down 43.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.7 billion (down 43.63% YoY), and the FY2025 annual result was $19.7 billion, down 18.24% from the prior year.
• Cash & Equivalents came in at $21.7 billion for Q1 2026 at Johnson & Johnson, up from $19.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $38.5 billion in Q1 2025 to a low of $10.5 billion in Q2 2022.
• The 5-year median for Cash & Equivalents is $19.7 billion (2023), against an average of $19.6 billion.
• Across the five-year window, Cash & Equivalents jumped 92.87% in 2023 and slumped 43.63% in 2026, its largest moves.
• Johnson & Johnson's Cash & Equivalents stood at $11.4 billion in 2022, then soared by 92.51% to $21.9 billion in 2023, then increased by 10.27% to $24.1 billion in 2024, then fell by 18.24% to $19.7 billion in 2025, then increased by 10.04% to $21.7 billion in 2026.
• The last three Cash & Equivalents figures came in at $21.7 billion (Q1 2026), $19.7 billion (Q4 2025), and $18.2 billion (Q3 2025), per Business Quant data.